Article
Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study).
The oncologist - 17 Mar 2023
Matsuoka Hiromichi, Tsurutani Junji, Chiba Yasutaka, Fujita Yoshihiko, Sakai Kiyohiro, Yoshida Takeshi, Nakura Miki, Sakamoto Ryo, Makimura Chihiro, Ohtake Yoichi, Tanaka Kaoru, Hayashi Hidetoshi, Takeda Masayuki, Okuno Tatsuya, Takegawa Naoki, Haratani Koji, Koyama Atsuko, Nishio Kazuto, Nakagawa Kazuhiko
Abstract excerpt
BACKGROUND: We hypothesized that the high-dose opioid requirement in patients carrying the rs4680-GG variant in the COMT gene encoding catechol-O-methyltransferase would be greater for patients taking morphine than for those taking oxycodone, thus providing a much-needed biomarker to inform opioid selection for cancer pain. METHODS: A randomized, multicenter, open-label trial was conducted at a Japanese...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.